Implementing Alfred60 AST in a clinical lab: Clinical impact on the management of septic patients and financial analysis

Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted antibiotic therapy. The Alfred60 system is able to provide phenotypic Antimicrobial Susceptibility Testing (AST) results within hours. This study...

Full description

Saved in:
Bibliographic Details
Published inAnnales pharmaceutiques françaises Vol. 81; no. 3; p. 466
Main Authors Potvin, M, Larranaga Lapique, E, Hites, M, Martiny, D
Format Journal Article
LanguageEnglish
Published France 01.05.2023
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted antibiotic therapy. The Alfred60 system is able to provide phenotypic Antimicrobial Susceptibility Testing (AST) results within hours. This study has two objectives: assess the clinical impact of this technology and determine its cost-effectiveness. During a ten-week period, all new enterobacterial or enterococcal bloodstream infection was analyzed with the Alfred60 system, in parallel with routine methods. Its impact on the clinician's therapeutic strategy was studied. In order to assess the financial and practical aspects of the method, an analysis of the extracosts and a survey of the technical staff were conducted. Fifty-three cases of bacteriemia were included. For the Enterobacteriaceae bacteriemias, a clinical impact was shown in 18.9% of the cases (e.g, treatment modification). The financial analysis highlighted an increase in costs (+38% for Enterobacteriaceae, +50% for Enterococci), compared to the theoretical costs reported by the firm, due to the workflow and the volumes of samples used. Finally, results of the technical staff survey were favorable in terms of ease of use of the system. In addition to its ease of use, the Alfred60 system is able to provide an AST in a record time. This study shows a real interest of the technique in the therapeutic management of patients with enterobacterial sepsis. However, its routine implementation requires an increase of the analyzed volumes as well as a 24/7 organization of the laboratory in order to be profitable.
AbstractList Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted antibiotic therapy. The Alfred60 system is able to provide phenotypic Antimicrobial Susceptibility Testing (AST) results within hours. This study has two objectives: assess the clinical impact of this technology and determine its cost-effectiveness. During a ten-week period, all new enterobacterial or enterococcal bloodstream infection was analyzed with the Alfred60 system, in parallel with routine methods. Its impact on the clinician's therapeutic strategy was studied. In order to assess the financial and practical aspects of the method, an analysis of the extracosts and a survey of the technical staff were conducted. Fifty-three cases of bacteriemia were included. For the Enterobacteriaceae bacteriemias, a clinical impact was shown in 18.9% of the cases (e.g, treatment modification). The financial analysis highlighted an increase in costs (+38% for Enterobacteriaceae, +50% for Enterococci), compared to the theoretical costs reported by the firm, due to the workflow and the volumes of samples used. Finally, results of the technical staff survey were favorable in terms of ease of use of the system. In addition to its ease of use, the Alfred60 system is able to provide an AST in a record time. This study shows a real interest of the technique in the therapeutic management of patients with enterobacterial sepsis. However, its routine implementation requires an increase of the analyzed volumes as well as a 24/7 organization of the laboratory in order to be profitable.
Author Hites, M
Martiny, D
Potvin, M
Larranaga Lapique, E
Author_xml – sequence: 1
  givenname: M
  surname: Potvin
  fullname: Potvin, M
  email: manon.potvin@lhub-ulb.be
  organization: Microbiology Department, LHUB-ULB, rue haute, 322, 1000 Brussels, Belgium. Electronic address: manon.potvin@lhub-ulb.be
– sequence: 2
  givenname: E
  surname: Larranaga Lapique
  fullname: Larranaga Lapique, E
  organization: Department of Infectious Disease, Erasme Hospital, route de Lennik, 808, 1070 Brussels, Belgium
– sequence: 3
  givenname: M
  surname: Hites
  fullname: Hites, M
  organization: Department of Infectious Disease, Erasme Hospital, route de Lennik, 808, 1070 Brussels, Belgium
– sequence: 4
  givenname: D
  surname: Martiny
  fullname: Martiny, D
  organization: Microbiology Department, LHUB-ULB, rue haute, 322, 1000 Brussels, Belgium
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36402206$$D View this record in MEDLINE/PubMed
BookMark eNqFjs0KwjAQhHNQrH-vIPsCQtpqQG9FFD3rvWzTVFeSbWgi6NtbRM-ehhm-GWYiBtyyGYixlDJfrtZyk4hJCPfeKZWmI5HkaiWzTKqxeJ6ct8YZjsRXKGzTmVpJKM4XIAYEbYlJowWL1RZ2P0fOo47QMsSbAYeM188ItA0E4yNp8BipTwIg19AQI2vqmz1qX4HCTAwbtMHMvzoVi8P-sjsu_aNypi59Rw67V_m7mv0F3iNSS58
ContentType Journal Article
Copyright Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.
Copyright_xml – notice: Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
MEDLINE with Full Text
Medline Complete
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 36402206
Genre Journal Article
GeographicLocations Belgium
GeographicLocations_xml – name: Belgium
GroupedDBID 08J
08T
0R~
457
53G
5GY
AAEDT
AALRI
AAXUO
AFNOS
AFTJW
AITUG
ALMA_UNASSIGNED_HOLDINGS
AOOFG
CGR
CUY
CVF
EBS
ECM
EIF
EJD
F5P
FDB
HZ~
NPM
O9-
P2P
RIG
SEM
SES
ID FETCH-pubmed_primary_364022062
ISSN 0003-4509
IngestDate Tue Oct 29 09:21:59 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Alfred60(AST)
Antibiogramme
Antimicrobial susceptibility testing
Bloodstream infections
Hémocultures
Rapid susceptibility testing
Sepsis
Bactériémies
Antibiogramme rapide
Blood cultures
Language English
License Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-pubmed_primary_364022062
PMID 36402206
ParticipantIDs pubmed_primary_36402206
PublicationCentury 2000
PublicationDate 2023-May
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: 2023-May
PublicationDecade 2020
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle Annales pharmaceutiques françaises
PublicationTitleAlternate Ann Pharm Fr
PublicationYear 2023
SSID ssj0036611
Score 4.6368985
Snippet Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted...
SourceID pubmed
SourceType Index Database
StartPage 466
SubjectTerms Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacteremia - diagnosis
Bacteremia - drug therapy
Belgium
Costs and Cost Analysis
Humans
Microbial Sensitivity Tests - economics
Microbial Sensitivity Tests - methods
Sepsis - diagnosis
Sepsis - drug therapy
Title Implementing Alfred60 AST in a clinical lab: Clinical impact on the management of septic patients and financial analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/36402206
Volume 81
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa8IwEA66wfBl7PdvuYfhizo6W1u7N5GJG24Ic-CbtDVhg1mLdWPur98lMWkmE9xeSm1qaft9zV0ud18IuYxGoe-jIaq6tcjCAYrPqmHIZSvrlHpcAC8Ua0Y-PLqdZ-d-UB_kcnMja-l9Fl5FX7_WlfwHVTyGuPIq2T8gqy-KB3Af8cUtIozbtTAW0r4i34fHNt7YlI5cq9x86vMohlH1iEjzkX9L_ValkTLFcawzYLjnmPI0l0jprUoFZ6ZlOYKFhonp0woNZpqWkxcdHufGpszQDIp5eI9PT2nfvTeZfUjhAh306QbTKb-JoNwNEv7nHyUSHfSK0x_nS-2DeZawvAhb1IwkQd0V21WnbvlmV9y4NihnG_2qI5dmMTBNxgJU23V4rfAarUuy2qopT_JeQ4yb79rKhNvotOilFvk9FsiWOn9p-CHckP4O2V6MH6ApybBLcjTeI6WefPXzCvSzerq0AiXoZdLk833yaTIGFGMAGQOvMQSgGAPImBtQfAHJF5jEgHyBjC8wYSD5AoovgHwBzRdQfDkgxfZtv9WpyqcaJlLkZKiet3ZINuJJTI8JuOHIGlG0jp7Lp9MZ9t2RZYWOZ9UYs6l1Qo5WXOR0ZcsZKWTsOCebDD9NeoF-3iwsCky-ATYqWwI
link.rule.ids 783
linkProvider Clarivate
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implementing+Alfred60+AST+in+a+clinical+lab%3A+Clinical+impact+on+the+management+of+septic+patients+and+financial+analysis&rft.jtitle=Annales+pharmaceutiques+fran%C3%A7aises&rft.au=Potvin%2C+M&rft.au=Larranaga+Lapique%2C+E&rft.au=Hites%2C+M&rft.au=Martiny%2C+D&rft.date=2023-05-01&rft.issn=0003-4509&rft.volume=81&rft.issue=3&rft.spage=466&rft_id=info%3Apmid%2F36402206&rft_id=info%3Apmid%2F36402206&rft.externalDocID=36402206
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4509&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4509&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4509&client=summon